-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Maintains Outperform on Opus Genetics, Raises Price Target to $10

Benzinga·03/12/2026 12:23:37
Listen to the news
Wedbush analyst Yun Zhong maintains Opus Genetics (NASDAQ:IRD) with a Outperform and raises the price target from $8 to $10.